| Literature DB >> 35910378 |
Sean M Collins1, Christopher J O'Connell1, Evan L Reeder1, Sophia V Norman2, Kainat Lungani2, Poornima Gopalan2, Gary A Gudelsky1,3, Matthew J Robson1,3.
Abstract
Various forms of traumatic brain injury (TBI) are a leading cause of disability in the United States, with the generation of neuropsychiatric complications such as depression, anxiety, social dysfunction, and suicidality being common comorbidities. Serotonin (5-HT) signaling is linked to psychiatric disorders; however, the effects of neurotrauma on normal, homeostatic 5-HT signaling within the central nervous system (CNS) have not been well characterized. We hypothesize that TBI alters specific components of 5-HT signaling within the CNS and that the elucidation of specific TBI-induced alterations in 5-HT signaling may identify novel targets for pharmacotherapies that ameliorate the neuropsychiatric complications of TBI. Herein, we provide evidence that closed-head blast-induced mild TBI (mTBI) results in selective alterations in cortical 5-HT2A receptor signaling. We find that mTBI increases in vivo cortical 5-HT2A receptor sensitivity and ex vivo radioligand binding at time points corresponding with mTBI-induced deficits in social behavior. In contrast, in vivo characterizations of 5-HT1A receptor function revealed no effect of mTBI. Notably, we find that repeated pharmacologic activation of 5-HT2A receptors post-injury reverses deficits in social dominance resulting from mTBI. Cumulatively, these studies provide evidence that mTBI drives alterations in cortical 5-HT2A receptor function and that selective targeting of TBI-elicited alterations in 5-HT2A receptor signaling may represent a promising avenue for the development of pharmacotherapies for TBI-induced generation of neuropsychiatric disorders.Entities:
Keywords: behavior; serotonin; serotonin 2A receptor (5-HT2A); social dominance; traumatic brain injury
Year: 2022 PMID: 35910378 PMCID: PMC9337880 DOI: 10.3389/fphar.2022.930346
Source DB: PubMed Journal: Front Pharmacol ISSN: 1663-9812 Impact factor: 5.988
FIGURE 1mTBI results in significant increases in RRT and altered locomotion following the injury. (A) mTBI results in significant increases in righting reflex time (RRT), indicative of a loss of consciousness in mTBI subjects as compared to their sham counterparts immediately following injury paradigm (t = 5.31, ***p ≤ 0.0001, N = 11 sham, 12 TBI). (B) Total locomotor activity three hours post-mTBI or sham paradigm. mTBI subjects exhibit a significant reduction in total locomotor activity acutely following injury paradigm (t = 4.22, **p ≤ 0.001, N = 7/group). (C) Locomotor activity binned over time revealed that mTBI subjects exhibit a reduction in exploratory activity immediately upon exposure to a novel environment [F (1,12) = 7.644, p = 0.017, t = 2.870, *p ≤ 0.05, N = 7/group] as compared to their sham counterparts.
FIGURE 2mTBI results in 5-HT2A receptor hypersensitivity and increased cortical 5-HT2A receptor binding. (A). 5-Hydroxytryptophan (5-HTP) administration (100 mg/kg, i.p.) results in a prototypic head twitch response (HTR), an effect derived from cortical 5-HT2A receptor activation. mTBI subjects exhibit a significant potentiation in HTR as compared to their sham counterpart subjects ten days post-injury [F (1,40) = 11.39, p = 0.0017, N = 11/group, post hoc analysis t = 4.57, ***p ≤ 0.001]. (B) Administration of the selective 5-HT2A receptor agonist DOI [1.0 mg/kg, i.p.] results in significant increases in HTR as compared to vehicle in sham subjects [F (3,85) = 118.1, p ≤ 0.0001, N = 6–10/group, post hoc analysis 3 days post-sham (N = 8 Sham-Vehicle, 10 TBI-Vehicle, 8 Sham-DOI, 9 TBI-DOI, t = 4.47, **p = 0.001), 10 days post-sham (N = 9 Sham-Vehicle, 10 TBI-Vehicle, 8 Sham-DOI, 9 TBI-DOI, t = 6.63, ***p ≤ 0.0001], and 30 days post-sham (N = 7 Sham-Vehicle, 6 TBI-Vehicle, 7 Sham-DOI, 6 TBI-DOI, t = 6.20, ***p ≤ 0.0001). Administration of DOI in mTBI subjects results in a potentiation of DOI-induced HTR, indicative of an increase in cortical 5-HT2A receptor sensitivity, as compared to sham subjects [F (6,85) = 4.39, p ≤ 0.001] both 3 (t = 6.14, ###p ≤ 0.0001) and 10 (t = 5.10, ###p ≤ 0.0001) days post-injury, an effect absent by 30 days post-injury. (C) Pretreatment with the 5-HT2A receptor antagonist M100907 mitigates DOI-induced HTR in sham subjects [Treatment (F (1,25) = 188.2, p ≤ 0.0001]; Interaction [F (1,25) = 11.37, p ≤ 0.01, N = 6 Sham-Vehicle-DOI, 8 TBI-Vehicle-DOI, 8 Sham-M100907-DOI, 7 TBI-M100907-DOI, t = 7.17, ***p ≤ 0.0001] and the potentiation of DOI-induced HTR in TBI subjects (t = 12.35, ***p ≤ 0.0001), indicative of a dependence on intact 5-HT2A receptor signaling in the mTBI-induced potentiation of DOI HTR. (D) Administration of the 5-HT1A agonist 8-OH-DPAT (0.1 mg/kg, i.p.) results in a significant, transient reduction in core body temperature in sham subjects, an effect unaltered by mTBI ten days post-injury (N = 12 Sham, 10 TBI), providing in vivo evidence of selective effects of mTBI on 5-HT2A receptor sensitivity. (E) No differences were found in htr2A (5-HT2A receptor) mRNA expression in mTBI subjects in either the PFC or SSC, as compared to their sham counterparts ten days post-injury (N = 5/group). (F) Ex vivo 5-HT2A receptor binding assays revealed mTBI-induced increases in 5-HT2A receptor binding within the frontal cortex at both 3 (N = 8/group, t = 2.18, *p ≤ 0.05) and 10 (N = 6 Sham, 7 TBI, t = 3.80, *p ≤ 0.05) days post-injury, time points corresponding to mTBI-induced potentiation of 5-HT2A-mediated HTR.
FIGURE 3mTBI results in deficits in sociability and altered social dominance. (A) Depiction of Crawley three-chamber sociability apparatus and representative heatmaps of sham and mTBI subjects ten days post-injury. mTBI subjects exhibit a reduction in interaction time with a novel conspecific, indicative of a reduction in general sociability. (B) Quantification of total time spent in the respective social chamber as compared to object chamber by sham or mTBI subjects. Sham mice exhibit a clear, significant preference for time spent in the social chamber containing a novel, gender, and age-matched conspecific subject [F (1,32) = 7.47, p ≤ 0.01, N = 10 Sham, 8 TBI, post hoc analysis (t = 3.57, **p ≤ 0.01], in stark contrast to mTBI subjects which fail to elicit any preference for the social interaction chamber as compared to the object chamber (t = 0.45, n. s.) 10 days post-injury. (C) Quantification of percent time spent specifically within the social interaction zone (depicted as circles within apparatus in 3A) with the novel, conspecific by sham and mTBI subjects 10 days post-injury. mTBI subjects fail to exhibit a significant social interaction zone preference, whereas sham subjects exhibit a clear social preference (t = 2.53, *p ≤ 0.05). (D) In concordance with deficits in sociability, the tube test for social dominance (depiction included) revealed a significant decrease in social dominance behavior 10 days post-injury in mTBI subjects (Fisher’s exact test, ***p ≤ 0.001, N = 15/group) when compared to their sham counterparts.
FIGURE 4Repeated pharmacologic 5-HT2A receptor activation ameliorates mTBI-elicited deficits in social dominance. (A) Low-dose DOI administration (0.1 mg/kg, (I) p., QD) was initiated three days post-injury or sham procedures, a time point where increased 5-HT2A receptor sensitivity is noted following mTBI. (B) One hour post-DOI administration 10 days post-injury, subjects were paired off in the tube test for social dominance. Again, we found that mTBI subjects administered vehicle exhibited a reduction in social dominance 10 days post-injury as compared to their sham counterparts (vehicle sham vs. vehicle mTBI, Fisher’s Exact Test, **p ≤ 0.01, N = 12/group). DOI administration in mTBI subjects attenuated social dominance deficits when compared to their sham vehicle administered counterparts (vehicle sham vs DOI mTBI, Fisher’s exact test, n. s., N = 12/group). Furthermore, mTBI subjects administered DOI exhibit a significant increase in social dominance behavior as compared to their vehicle-treated mTBI counterparts (vehicle mTBI vs. DOI mTBI, Fisher’s exact test, **p ≤ 0.01, N = 12/group). It should be noted that DOI administration in sham subjects exerts a small, albeit significant increase in social dominance behavior as compared to vehicle-treated sham subjects (vehicle sham vs. DOI sham, Fisher’s exact test, *p ≤ 0.05, N = 12/group), an effect pointing to a role of 5-HT2A receptor signaling in regulating the social dominance behavior under normal physiologic conditions.